Suzhou Novoprotein Scientific Co., Ltd. Class A
SSSE:688137106.80
CNY
-26.70
(-20.00%)
ISIN
CNE100005NZ4
Return %
Stock
S&P 500
1Y
157.60
14.20
3Y
123.38
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Hua Xing Zhu
- Full Time Employees
- 636
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Suzhou China
- IPO Date
- Sep 29, 2022
- Website
- novoprotein.com.cn
- Similar Companies
- Business
- Suzhou Novoprotein Scientific Co., Ltd. Class A is a China-based biotechnology company engaged in the research, development, manufacture, and commercialization of recombinant proteins, molecular enzymes, and critical upstream raw materials for biopharmaceutical research, in vitro diagnostics, and cell and gene therapies. The company operates across four primary business segments: Target Proteins, Molecular Biology Enzymes, In Vitro Diagnostic Raw Materials, and Contract Research and Development Services. Its product portfolio comprises recombinant target proteins and cytokines, including GMP-grade cell culture cytokines, growth factors, interleukins, chemokines, immune checkpoint proteins, and viral antigens; mRNA synthesis enzymes and molecular reagents, including T7 RNA polymerases, mRNA capping enzymes, Poly(A) polymerases, inorganic pyrophosphatases, RNase inhibitors, reverse transcriptases, high-fidelity PCR and qPCR enzymes, isothermal amplification reagents, and next-generation sequencing library preparation kits; diagnostic raw materials, including specialized diagnostic antibodies, recombinant antigens, and blocking agents for chemiluminescence, ELISA, and lateral flow assays; and gene editing enzymes, including GMP-compliant Cas9, Cas12a, and Cas13 nucleases. The company also provides specialized contract research and development services, encompassing recombinant protein expression and purification across multiple host systems; antibody engineering and screening; directed enzyme evolution; and end-to-end mRNA contract development and manufacturing organization services spanning plasmid preparation, in vitro transcription, lipid nanoparticle encapsulation, and analytical characterization. Suzhou Novoprotein Scientific serves biopharmaceutical manufacturers, in vitro diagnostic companies, contract research organizations, and academic and medical research institutes across mainland China, North America, Europe, and the Asia-Pacific region. In recent developments, the company has expanded its commercial offerings with integrated, clinical-grade mRNA-LNP solutions to support therapeutic mRNA vaccine and drug development, while scaling its GMP-grade industrial manufacturing infrastructure to meet stringent international quality and regulatory standards. Additionally, the company has accelerated its international expansion by establishing strategic distribution partnerships and deepening commercial collaborations with biopharmaceutical and diagnostic developers globally to facilitate supply chain localization and global delivery. Founded in 2009, Suzhou Novoprotein Scientific Co., Ltd. is headquartered in Suzhou, Jiangsu Province, China.